Sanofi-Aventis and DNDi sign agreement on trypanosomiasis drug
26 May 2009
Becky Debens
Please Login to read the full article.
26 May 2009
Becky Debens
becky.debens@informa.com
A potential new compound to treat the parasitic disease African trypanosomiasis is set to enter clinical development, following an agreement between the Drugs for Neglected Diseases initiative ( DNDi) and Sanofi-Aventis.
Fexinidazole, an antiprotozoal compound, will be the only new drug currently...
Please Login to read the full article.
RELATED CONTENT
NEWS
- WHO hopes Gilead's expanded support for leishmaniasis control will encourage others
- US Capitol Capsule: With wish granted, Collins forges ahead with new translational science centre
- Stem cell death for cash-crunched Geron, Angiotech, but Mesoblast outlasts them
- Celtic merges funds to create Anglo-Russian newco promising free medicines to Africa
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
